Response Rates (at least 50% reduction in depression) | |||
---|---|---|---|
AD (%) | Placebo (%) | Difference | |
S3-guidelines summary statement on efficacy these were based on: | 50–60 | 25–35 | ca. 25 |
1. Walsh et al. (2002) [19] | 50 | 30 | 20 |
2. Oeljeschläger et al. (2004) [18]a | 67 | 47 | 20 |
Current Meta-Analyses | |||
Cipriani et al. (2018) [20]b | ca. 50 | ca. 40 | ca. 10 |
Jakobsen et al. (2017) [21]c | 49 | 39 | 10 |
Meta-Analyses available before the last update of the S3-guidelines | |||
Furukawa et al. (2016) [23] | 35–40 | ||
Weitz et al. (2015) [24] | 42 (Duloxetine) 45 (SSRIs) | 24 | 18–21 |
Nelson et al. (2013) [7] | 49 | 40 | 9 |
Gibbons et al. (2012) [6] | |||
mild depression | 55 | 37 | 18 |
severe depression | 58 | 41 | 17 |
Undurraga & Baldessarini (2012) [25] | 54 | 37 | 17 |
Melander et al. (2008) (SSRI + SNRI) [26] | 48 | 32 | 16 |
Arroll et al. (2005) [27] | SSRI: 56 | 41 | 15 |
TCI: 60 | 47 | 13 | |
Storosum et al. (2004) (only TCA) [28] | 39 | 28 | 11 |